Overall, patients with synucleinopathies died about two years earlier than participants without in the comparison group. (sciencedaily.com)
As we have seen, both active vaccination with AFFiRiS» AFFITOPE AFF 1 / PD01A vaccine and passive vaccination with Prothena's AS - targeting mAbs (one of which presumably was humanized to develop PRX002) were effective in rescuing neuronal loss, synaptic degeneration, neuroinflammation, and cognitive and behavioral deficits in two mouse models of synucleinopathies of aging. (sens.org)
As recently as two years ago, there was little evidence of any academic or biotech industry interest in pursuing clearance of AS as a therapeutic approach to PD, LBD, or other synucleinopathies of aging: after a promising 2005 report, [31] there had been virtual silence. (sens.org)